Compare Ecopetrol SA (EC) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Ecopetrol SA trades at $17.93 (market cap $33.52B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Ecopetrol SA is far larger — about 34.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Ecopetrol SA pays a 3.71% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecopetrol SA for 84 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EC | MRVI | |
|---|---|---|
Market Cap | $33.52B | $972.90M |
Volume | 1,602,222 | 4,325,710 |
Sector | Energy | Health |
52-Week High | $18.26 | $9.00 |
52-Week Low | $8.61 | $2.83 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $62.13B | $1.08B |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $17.90, up 3.89% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. Revenue has declined from $159.61T in 2022 to $119.69T in 2025, with net income margin falling to 8.76%. Recent management changes and board appointments signal corporate transformation efforts, while analyst consensus is cautious with a 'Reduce' rating and $16.85 price target.
The stock faces headwinds from declining profitability and revenue, offset by low valuation multiples (P/E 8.27, EV/EBITDA 4). Risks include political influence, corruption probes, and oil price volatility. Upside depends on execution under new leadership and stabilization of financials, but current sentiment remains neutral to bearish amid operational challenges.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
